肝癌治疗进展2010ppt课件.pptVIP

* * * The purpose of this phase III randomized, double-blind, placebo-controlled study is to evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of HCC after potentially curative treatment. The primary end point for this trial is RFS.The secondary end points include:Time to recurrence (TTR),OS,Patient-reported outcomes (PROs) as assessed by the FACT-Hep and the EQ-5D questionnaire. The evaluation of biomarkers. The estimated enrollment for this trial is 1100 patients. Patients randomized to the experimental arm will receive sorafenib 400 mg bid, while patients